Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study explores shorter teprotumumab courses for thyroid eye disease

NCT ID NCT05002998

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how safe and tolerable different lengths of treatment with teprotumumab are for adults with thyroid eye disease (TED). About 313 participants received the drug for varying durations to see if shorter treatment works as well and reduces side effects. The goal is to find the best dosing schedule and understand if some people need re-treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE

Contacts and locations

Locations

  • ARNAS Garibaldi - PO Garibaldi-Centro

    Catania, Sicily, 95124, Italy

  • ASST dei Sette Laghi - Ospedale Di Circolo E Fondazione Macchi

    Varese, Lombardy, 21100, Italy

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Campania, 80131, Italy

  • Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara

    Pisa, Tuscany, 56126, Italy

  • Bascom Palmer Eye Institute

    Miami, Florida, 33136-1119, United States

  • Casey Eye Institute - OHSU

    Portland, Oregon, 97239-3130, United States

  • Centre Hospitalier National D'ophtalmologie Des Quinze Vingts

    Paris, 75571, France

  • Hopital Jean Minjoz

    Besançon, Doubs, 25030, France

  • Hospices Civils de Lyon - Hôpital Louis Pradel

    Bron, Rhône, 69677, France

  • Hospital La Arruzafa

    Córdoba, Córdoba, 14012, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario Virgen Macarena

    Seville, 41009, Spain

  • Hôpital Claude Huriez-Lille-Rue Michel Polonovski

    Lille, 59000, France

  • Imperial College Healthcare NHS Trust - PPDS

    London, London, City of, W21 1NY, United Kingdom

  • Mayo Clinic - PPDS

    Rochester, Minnesota, 55905-0001, United States

  • Moorfields Eye Hospital - PPDS

    London, London, City of, EC1V 2PD, United Kingdom

  • Royal Victoria Infirmary

    Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom

  • Southampton University Hospitals NHS Trust

    Southampton, SO16 9YD, United Kingdom

  • Stanford University

    Palo Alto, California, 94303-3216, United States

  • The Private Practice of Raymond Douglas, MD - Beverly Hills

    Beverly Hills, California, 90210-5192, United States

  • USC Roski Eye Institute - Los Angeles

    Los Angeles, California, 90033, United States

  • University Hospital of Cardiff

    Cardiff, South Glamorgan, CF11 0SN, United Kingdom

  • University Medicine Göttingen Germany

    Göttingen, Lower Saxony, 37075, Germany

  • University of Colorado - Eye Center - PPDS

    Aurora, Colorado, 80045-2517, United States

  • Universitätsklinikum Essen

    Essen, 45122, Germany

  • Universitätsklinikum Münster

    Münster, 48149, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, Rhineland-Palatinate, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.